Meropenem Milpharm

Meropenem Trihydrate, the active ingredient in Meropenem Milpharm, is a carbapenem antibiotic presented as a powder for solution for injection for intravenous use. It is employed to treat severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired pneumonia, ventilator‑associated pneumonia, and severe sepsis or septic shock in hospitalized patients.

GNH USA supplies Meropenem Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier providing reliable service to hospitals, transplant centres, oncology centres, pharmacies and clinics across the globe worldwide today.

Meropenem is a carbapenem antibiotic that targets resistant Gram‑negative and Gram‑positive bacteria in serious infections.

- Complicated intra‑abdominal infections: achieves clinical cure and microbiological eradication in patients with peritonitis or intra‑abdominal abscesses. - Complicated urinary tract infections: resolves infection and prevents recurrence in patients with pyelonephritis or obstructive uropathy. - Hospital‑acquired pneumonia: improves survival and clears pulmonary infection caused by multidrug‑resistant organisms. - Ventilator‑associated pneumonia: provides effective bacterial clearance in intubated patients with ventilator‑related lung infection. - Severe sepsis and septic shock: rapidly reduces bacterial load, supporting hemodynamic stabilization in critically ill patients.

Adverse reactions to Meropenem may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset that may resolve spontaneously. - Diarrhea: loose stools that can range from mild to moderate severity. - Rash: skin erythema or mild itching that usually does not require discontinuation.

Serious or Rare Side Effects: - Seizures, particularly in patients with renal dysfunction or pre‑existing CNS disorders. - Anaphylaxis or severe hypersensitivity reactions, presenting with hives, bronchospasm or hypotension. - Clostridioides difficile‑associated colitis, causing severe watery diarrhea and abdominal pain.

When using Meropenem, clinicians should consider several precautionary measures to ensure safe therapy.

- Renal function: adjust dose in patients with impaired creatinine clearance. - Allergy history: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. - Seizure risk: monitor closely in patients with central nervous system disorders or receiving high doses. - Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant. - Drug interactions: review concomitant medications for possible pharmacodynamic or pharmacokinetic effects. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, requiring avoidance or careful monitoring.

Major Interactions (Avoid): - Valproic acid: reduces valproate serum concentrations, which may compromise seizure control and require dose adjustment. - Probenecid: raises meropenem plasma levels, increasing the risk of nephrotoxicity and neurotoxicity. - Aminoglycosides: combined use heightens nephrotoxic potential and may require renal function monitoring.

Moderate Interactions (Monitor Closely): - Diuretics: may cause electrolyte disturbances that can affect meropenem efficacy and renal handling. - NSAIDs: concurrent administration can aggravate renal impairment, especially in patients with pre‑existing kidney disease.